Posted by Michael Wonder on 07 Sep 2023
Inflation Reduction Act may accelerate generic and biosimilar market entry, but questions remain around CMS guidance
5 September 2023 - Last week, the Centers for Medicare and Medicaid Services announced its selection of the first 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act.
Conspicuously, four of the drugs CMS included in the first batch of 10 face generic or biosimilar competition before or during 2026 when the “maximum fair prices” will get implemented.
Another pharmaceutical which CMS chose is more than 25 years past its initial date of approval by the FDA.
